Biotechnology
Gene editing, cancer biotechnology, regenerative medicine, longevity science and the evidence moving from laboratories into clinical care.
-
Personalised mRNA Cancer Vaccine Cuts Melanoma Recurrence Risk in Phase III
A 1,137-person Phase III trial found that adding an individualised mRNA therapy to Keytruda reduced the risk of melanoma recurrence or death by 42%. The result is important, but it is not yet an approval or proof of benefit in other cancers.
-
Tarlatamab Combination Extends Survival in First-Line Small-Cell Lung Cancer
In the Phase III DeLLphi-305 trial, tarlatamab plus durvalumab extended median overall survival to 21.1 months after initial chemotherapy. The benefit was substantial, alongside higher serious treatment-related toxicity and frequent cytokine release syndrome.
-
Human-Embryo Base Editing Improves Precision but Still Triggers Safety Alarms
A Nature study achieved efficient adenine base editing in research-stage human embryos without the large deletions typical of DNA-cutting CRISPR. Rare chromosome damage, mosaic off-target edits and embryo arrest still rule out reproductive use.
-
Dual-Target ADC Doubles Progression-Free Survival in Advanced Breast Cancer
Phase 3 results for iza-bren improved progression-free survival after prior chemotherapy, while overall-survival data remain immature and approval is not yet established.
-
Brezosiran Cuts a Huntington’s Protein Marker, Not Yet the Disease
Initial Phase 1b data show deep, durable lowering of mutant huntingtin in spinal fluid. Whether that changes symptoms or progression remains unanswered.
-
Cellular Recycling Failure Helps Senescent Cells Linger in Ageing Mice
A Nature Aging study links weaker chaperone-mediated autophagy to failed immune clearance of senescent cells—but the intervention remains preclinical.
-
CAR-T Therapy Shows Early MS Activity Alongside a Fatal Safety Event
A 66-person Phase 1 study of zola-cel reported encouraging MRI and disability signals, but also serious neurotoxicity and one death after intensive immune suppression.
-
An 82% Response Rate in Pancreatic Cancer Still Needs a Randomised Test
A small Phase I/II study has reported tumour responses in 82% of evaluable patients with a biomarker-defined form of advanced pancreatic cancer. The result is striking, but the non-randomised dataset cannot show how much benefit the combination adds.
-
Two Embryonic Lineages Reframe How Scientists Build Hindbrain Neurons
Lineage tracing in mouse embryos and experiments with human pluripotent stem cells suggest that forebrain and hindbrain neurons arise through parallel developmental routes. The work may sharpen laboratory models, but it is not a stem-cell treatment.
-
AI-Designed Protein Shells Carry RNA, but the Evidence Remains Preclinical
Researchers have built synthetic protein assemblies that package and transfer RNA, including a CRISPR cargo tested in patient-derived cells and pig muscle cells. The platform is inventive, but it has not been administered to people.
-
ER-100 Reaches Humans, but Three Glaucoma Patients Cannot Prove Rejuvenation
Life Biosciences has reported the first three participants in a Phase I trial of ER-100. The safety update permits dose escalation, but the tiny open-label dataset cannot establish restored vision or human rejuvenation.
-
BioNTech Rebuilds a Phase III Breast-Cancer Trial Around Trodelvy
BioNTech plans to compare pumitamig plus Trodelvy with Trodelvy alone in a redesigned Phase III trial for PD-L1-low or negative triple-negative breast cancer. The change raises the clinical bar; the combination remains unapproved.